Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04134559 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv12
  2. Primary completion date: Jan 1, 2025 to Jan 1, 2027
    • Study completion date: Jan 1, 2025 to Jan 1, 2028
    v11
  3. Re-verified, no change to tracked fieldsv10
  4. Lead sponsor: Allison O'Neill to Allison O'Neill, MDv9
  5. Primary and study completion dates: Jan 1, 2023 to Jan 1, 2025
    • Study sites: 4 to 5
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Eligibility criteria expanded, about 85 wordsv7
  2. Study sites: 2 to 4
    • Start date changed from estimate of Oct 2020 to Nov 1, 2020
    v6
  3. Start date: Mar 2020 to Oct 2020v5
  4. Start date: Feb 2020 to Mar 2020v4
  5. Start date: Nov 2019 to Feb 2020v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2019 to Nov 2019
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Trial Details
NCT Number NCT04134559
Lead Sponsor Allison O'Neill, MD
Conditions
(from sponsor)		 Hepatocellular Carcinoma, Childhood, Fibrolamellar Carcinoma, Liver Cancer, Liver Cancer, Pediatric
Related terms Carcinoma, Hepatocellular, Fibrolamellar hepatocellular carcinoma, Liver Neoplasms
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov